コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 PBSC (> or = 7.5 x 10(8) nucleated cells/kg) were collec
2 PBSC collection was done after two induction cycles.
3 PBSC collections were initiated when the WBC count recov
4 PBSC donors were treated with 5 to 7 days of filgrastim
5 PBSC harvests were processed each day on a single avidin
6 PBSC patients were discharged from hospital earlier than
7 PBSC transplant recipients were older, and were more lik
8 PBSC transplants contained higher doses of DC2 than marr
9 PBSC were collected from 229 patients from the purged gr
10 PBSC were enriched for the CD34+ population with and wit
11 PBSC were mobilized with high dose cyclophosphamide and
12 PBSCs are a preferred source of stem cells for many type
13 PBSCs mobilized by GRObeta (GRObeta(Delta4)/CXCL2(Delta4
14 PBSCs mobilized by GRObeta(Delta4) alone or with G-CSF c
15 PBSCs mobilized with pSCF/pIL-3 were infused into an SLA
16 PBSCs were collected after mobilization with chemotherap
17 PBSCs were mobilized at steady state (n = 2), after gran
19 luate the peripheral blood lymphocytes of 22 PBSC donors and 22 matched controls at 5 time points ove
20 port a prospective study of 2726 BM and 6768 PBSC donors who underwent collection from 2004 to 2009.
23 the recommendation for ATG to be added after PBSC transplantation, no obvious benefit was identified
25 grade 1 and two with grade 2) 100 days after PBSC repeat infusion, compared with three patients (two
28 ilar, but chronic GVHD risk was higher after PBSC transplantation (relative risk [RR], 1.85; 95% CI,
34 ransplant-related mortality after allogeneic PBSC transplantation will require more effective strateg
35 a high risk of chronic GVHD after allogeneic PBSC transplantation, which compromised the performance
36 tation from HLA-identical donors, allogeneic PBSC transplantation from HLA-identical donors is associ
39 ears to be safe in donors with SCT, allowing PBSC use for transplantation in patients with sickle cel
40 ant differences were observed between BM and PBSC donors regarding pain, blood allotransfusion, durat
49 imilar to that observed following autologous PBSC transplant, with an absolute neutrophil count (ANC)
51 nalysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marke
52 by the infusion of CD34-selected autologous PBSC were assessed for the development of CMV disease in
53 ve patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, wit
54 Thus, prolonged engraftment of autologous PBSCs and continued expression of the transduced gene ca
55 nstituted with BALB/c (H-2(d))+BXSB (H-2(b)) PBSCs, in which the number of injected allogeneic progen
56 bone marrow/peripheral blood stem cells (BM/PBSCs), unrelated BM/PBSCs, and unrelated cord blood rec
58 other hand, increases in the number of BXSB PBSCs resulted in the transfer of lupus nephritis in BXS
60 CD34(+) peripheral blood stem cells (CD34(+)PBSCs) with lentivector-gp91(phox) or amphotropic oncore
61 gnificant ex vivo correction of X-CGD CD34(+)PBSCs (18% and 54% of cells expressing gp91(phox), assoc
63 ced CD34+ peripheral blood stem cells (CD34+ PBSCs) from this trial transplanted into nonobese diabet
64 n of NOD/SCID mouse repopulating X-CGD CD34+ PBSCs (14%-22% corrected human neutrophils; human cell e
65 ein to allow similar studies of normal CD34+ PBSCs, we show that progressively higher levels of gene
67 ed of autologous peripheral blood stem cell (PBSC) collection in 27, followed by transplantation in 2
69 ow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent collection of PBSC or BM betw
70 studied whether peripheral blood stem cell (PBSC) graft iNKT-cell dose affects on the occurrence of
71 Unfractionated peripheral blood stem cell (PBSC) grafts contain measurable quantities of myeloma ce
72 human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GVHD and provide sufficient nu
76 d feasibility of peripheral blood stem cell (PBSC) mobilization in 8 SCT subjects and 8 control subje
77 able estimate of peripheral blood stem cell (PBSC) mobilization response to granulocyte colony-stimul
78 ous schedules of peripheral blood stem cell (PBSC) reinfusion, granulocyte colony-stimulating factor
79 with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of maligna
80 doxorubicin and peripheral blood stem cell (PBSC) support in advanced medullary thyroid cancer (MTC)
81 nor T cells from peripheral blood stem cell (PBSC) transplant allografts ex vivo using an anti-CD25 i
82 ng an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical (n = 14) or a 5/6
86 sus conventional peripheral blood stem cell (PBSC) transplants from HLA-matched siblings were compare
89 38 marrow and 31 peripheral blood stem cell [PBSC]) donors participating in a randomized trial compar
91 sed to mobilize peripheral blood stem cells (PBSC) from normal donors, has led to the use of PBSC as
92 Recipients of peripheral blood stem cells (PBSC) had faster recovery and fewer platelet transfusion
95 currently using peripheral blood stem cells (PBSC) mobilized by chemotherapy and recombinant growth f
96 n of allogeneic peripheral blood stem cells (PBSC) mobilized by either recombinant canine granulocyte
98 plantation with peripheral blood stem cells (PBSC) results in faster haematopoietic-cell repopulation
103 d peripheral blood hematopoietic stem cells (PBSCs) demonstrate accelerated engraftment compared with
104 in which human peripheral blood stem cells (PBSCs) differentiate along megakaryocytic as well as mye
105 tients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, and 23 received bone
106 tients received peripheral blood stem cells (PBSCs) from matched-related donors, 2 received PBSCs fro
111 supported with peripheral-blood stem cells (PBSCs) is related to the dose of CD34(+) cells infused.
112 plus allogeneic peripheral blood stem cells (PBSCs) is sufficient to interrupt autoimmune processes i
113 atients who had peripheral-blood stem cells (PBSCs) mobilized with filgrastim or the sequential regim
115 l population of peripheral blood stem cells (PBSCs) of three asymptomatic HIV-1-infected individuals
116 ologous CD34(+) peripheral blood stem cells (PBSCs) that had been transduced ex vivo with a recombina
117 ical allogeneic peripheral blood stem cells (PBSCs) that were selected for CD34+ cells by an avidin-b
118 34(+) peripheral blood-mobilized stem cells (PBSCs) with retrovirus vector encoding wild-type (wt) CX
119 f HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients of unrelated donor BM transpl
124 ed peripheral blood progenitor (stem) cells (PBSCs) have recently become the preferred source for hem
125 (bone marrow vs peripheral blood stem cells [PBSCs]), age, sex, graft-versus-host disease (GVHD), ste
127 ychology and Behavioral Sciences Collection [PBSC]) was conducted from database inception to May 2012
129 collected, a direct comparison of concurrent PBSC versus BM donation experiences has not been perform
130 years (median, 46 years), given conventional PBSC transplants following high-dose conditioning and po
131 X (10% with > or = 50% tumor cytoreduction), PBSC mobilization with HDCTX should be limited to select
133 ation and chemical lysis was used to deplete PBSC collections of monocytes, granulocytes, erythrocyte
135 erly patients receiving selectively depleted PBSC transplants from HLA-identical sibling donors.
136 nts with high-risk leukemia with TN-depleted PBSC grafts following conditioning with total body irrad
138 s toxic conditioning regimens are developed, PBSC transplantation might provide a new solution to all
141 survival rate for a 2.0-GBq injection dose, PBSC dosimetry suggested a time interval of 13 d after r
142 imetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radio
143 starting with administration of filgrastim (PBSC donors) or after the marrow collection procedure.
144 he median time to progression from the first PBSC reinfusion was 49.5 weeks (range, 8 to 156+ weeks).
147 sed risk for SAEs (2.38% for BM vs 0.56% for PBSC; odds ratio [OR], 4.13; P < .001), and women were t
149 administration of G-CSF to normal donors for PBSC collection appears safe, longer follow-up is requir
150 veloping fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB.
151 veloped for optimizing the time interval for PBSC infusion after high-dose radionuclide therapy.
158 w that (1) multilineage engraftment of human PBSC can be achieved in the fetal rhesus recipient, (2)
160 clusion, xenogeneic transplantation of human PBSCs into NOD/SCID mice provides an excellent in vivo m
161 cess wt CXCR4 expression by transduced human PBSCs enhanced marrow engraftment, but did not affect bo
162 rowth factors with proven utility to improve PBSC mobilization and maximize our PBSC procurement thro
163 lusion, higher doses of CD4(-) iNKT cells in PBSC grafts are associated with protection from aGVHD.
168 edian CD34+ cell content was also similar in PBSCs collected from SCT versus control subjects, 6.8 ve
169 rget for G-CSF and GRObeta/GRObetaT-mediated PBSC mobilization and, importantly, that synergistic mob
173 L2 and GRObetaT/CXCL2Delta4 rapidly mobilize PBSC equivalent to granulocyte colony-stimulating factor
176 udy, we investigated whether G-CSF-mobilized PBSC maintain their GVL effect in a murine allogeneic tr
177 cute GVHD after transplantation of mobilized PBSC were not different than previously reported for non
181 data suggest that GRObeta(Delta4)-mobilized PBSCs are superior in reconstituting long-term hematopoi
185 PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity condi
186 has led to tentative suggestions that normal PBSCs could be collected and used for autologous transpl
188 ll (PBSC) donors who underwent collection of PBSC or BM between 2004 and 2009 as part of a prospectiv
189 antly longer time interval for completion of PBSC collection than group 1 (median, 22 v 8 days; P = .
191 ed with lower morbidity, shorter duration of PBSC mobilization, and comparable hematopoietic recovery
192 e sought to evaluate whether the infusion of PBSC grafts containing lysed red blood cells (RBCs) lead
195 il regarding individualized risk patterns of PBSC versus BM donation toxicity, suggesting donor profi
202 -CSF, followed by collections at the time of PBSC harvest (days 5-7) and at 2, 6, and 12 months after
203 Given the trend toward increased use of PBSC allografts in children, prospective clinical trials
204 C) from normal donors, has led to the use of PBSC as a major alternative to bone marrow for patients
208 er somewhat in the number and composition of PBSCs and effector cells mobilized to the peripheral blo
209 ninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs wi
212 our laboratory, procurement of a megadose of PBSCs is necessary for on-going studies evaluating non-m
213 New strategies for rapid mobilization of PBSCs from normal donors using plerixafor have been repo
215 nic GVHD developed in 39 of 63 recipients of PBSCs and in 32 of 63 BM recipients who were alive and f
220 emotherapy regimens and patient variables on PBSC collections as measured by the yield of CD34+ cells
221 re infused with either bone marrow (n=19) or PBSC (n=20) after standard conditioning regimens in a do
222 eceived T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS-free survival of the chimer
223 o improve PBSC mobilization and maximize our PBSC procurement through an automated collection procedu
226 mprove engraftment, which suggests that poor PBSC mobilization usually indicates poor marrow function
228 e factors, progenitor numbers returned, post-PBSC G-CSF, and hematologic recovery was performed in 81
240 SCs) from matched-related donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem
242 in determining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher a
243 transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD
244 I + BM, MA + nonTBI + BM, RIC + BM, or RIC + PBSCs had lower risks of grades B-D AGVHD than those in
251 e did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients w
252 ble that transplantation of G-CSF-stimulated PBSC does not result in overwhelming acute GVHD because
253 d Nov 16, 2012, 174 patients with sufficient PBSCs were randomised to salvage ASCT (n=89) or cyclopho
255 y to decide upon a minimum dose of syngeneic PBSCs to achieve the desired beneficial effects on autoi
256 ing (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) M
260 sis of our experience, we would suggest that PBSCs should be the stem cell source of choice in childr
265 ng grades 2 to 4 acute GVHD were 37% for the PBSC group and 56% for the BM group (P = .18), while the
266 ficantly increased numbers of T cells in the PBSC graft, acute graft-versus-host disease (GVHD) is no
268 higher in the bone-marrow group than in the PBSC group (p=0.01); all five relapses occurred among bo
269 s (0.04 vs 0.08, p=0.007) were higher in the PBSC group, and the proportion of patients with absolute
270 o 4.7 x higher numbers of CD34+ cells in the PBSC product than the same total dose given once a day (
271 ly measurement of the CD34(+) content of the PBSC collection was performed by a central laboratory us
274 1995, 44 patients with MM were randomized to PBSC mobilization with either granulocyte colony-stimula
276 optosis of neutrophils arising in transduced PBSC cultures even with stimulation by a CXCR4 agonist,
278 lly delayed when compared with unmanipulated PBSC grafts; one patient required infusion of a reserve
285 cell hematopoietic cell transplantation (URD-PBSC HCT) for acute myeloid leukemia, acute lymphoblasti
287 ferences between the groups undergoing BM vs PBSC donation preclude direct risk comparisons between t
293 nse received myeloablative chemotherapy with PBSC rescue and radiation to the presurgical primary tum
298 nt autologous stem-cell transplantation with PBSC as randomly assigned after six cycles of induction
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。